Group 1 - The size and style rotation strategy based on "monetary-credit-short and long-term style momentum" has achieved an annualized return of 17.9% since 2015, with a monthly win rate of 60.5%, demonstrating a stable ability to generate excess returns [2][16][23] - The strategy has accumulated a return of 87.5% since its release in July 2024, outperforming the equal-weight strategy by 22 percentage points [2][23] - The introduction of seasonal factors has improved the annualized return of the size and style rotation strategy by 1.9 percentage points since 2015, increasing it to 19.8% [32][53] Group 2 - Seasonal analysis indicates that large-cap styles dominate in December, January, and April, while small-cap styles show superiority in February, with a win rate of 91.7% [28][35] - The seasonal signal has a historical win rate of 58.6% since 2015, with the highest win rates for small-cap recommendations in February and large-cap in April [28][35] - The strategy effectively reduces drawdowns compared to the equal-weight portfolio, showcasing its risk control capabilities [20][23] Group 3 - The improved rotation model incorporates seasonal and crowding factors, using a six-factor equal-weight voting system that reflects macroeconomic conditions, style momentum, seasonality, and trading crowding [53][59] - The model has achieved an annualized return of 20.2% since 2015, outperforming the four-factor style rotation model by 2.3 percentage points [53][51] - The strategy has consistently outperformed the benchmark since 2015, with a monthly win rate of 63.7% [59]

Investment Rating - The report maintains a "Recommended" rating for Kelun-Biotech (6990.HK) [3][6][13] Core Insights - The company is transitioning towards an integrated R&D and sales model, with its core product sac-TMT having received approval for four indications domestically and is undergoing 17 global Phase III clinical trials [4][6] - In 2025, the company achieved revenue of 2.058 billion yuan, with drug sales contributing 543 million yuan and licensing and collaboration income reaching 1.5 billion yuan [3][4] - The company has established strategic partnerships with major firms such as Merck and others to expand its product offerings and market reach [3][4] Financial Summary - Revenue projections for 2026 and 2027 have been adjusted to 2.3 billion yuan and 3.337 billion yuan respectively, with a new forecast for 2028 set at 5.362 billion yuan [6][11] - The company reported a net loss of 382 million yuan in 2025, with expectations of a return to profitability in 2027 with a projected net profit of 36 million yuan [5][11] - The gross margin is expected to improve from 71.9% in 2025 to 78.0% by 2028, indicating enhanced operational efficiency [5][11] Product Pipeline - The core product sac-TMT is involved in multiple clinical trials, including studies for treating TNBC and NSCLC, with significant data showing improved overall survival rates [4][6] - The company has a diverse product matrix, including ADCs, immune therapies, and small molecules, with several products already approved and others in various stages of clinical trials [6][10]

1. Report Industry Investment Rating - The report does not mention the industry investment rating. 2. Core Viewpoints of the Report - The one - package debt - resolution policy has effectively curbed the growth of local debt and mitigated debt risks, but the scale of local debt still rises, and future policies and risks need re - evaluation [5]. - Most debt - resolution policies will gradually withdraw, but policies on urban investment bonds may continue. The focus will be on accelerating the clearance of financing platforms and promoting their substantial transformation [65][74]. - The credit spreads of urban investment bonds may widen, and investors are advised to be cautious and select regions with valuation safety margins and entities with clear government support [80][84]. 3. Summary According to the Directory 3.1 Policy Review: Continued Debt - Resolution Ideas and Strengthened Debt - Resolution Efforts - **Policy Background**: From 2022 to 2023, the local fiscal self - sufficiency rate declined, the local fiscal revenue decreased, and the expenditure increased, leading to intensified fiscal revenue - expenditure contradictions. Multiple regions faced debt risk hidden dangers, which prompted the introduction of the one - package debt - resolution plan [6][8]. - **Policy Framework**: After July 2023, fiscal and financial policies supported the resolution of local government illegal debts and financing platform debts respectively. The policy ideas were generally consistent with the previous round, but the scope of debt expanded and focused on key provinces. The policy also adopted a list - based management model [11][14]. - **Local Government Illegal Debts**: In terms of stock resolution, the types of debts that can be repaid by local government generalized replacement bonds expanded, the scale increased significantly, and the regions were more concentrated. In terms of increment constraint, Document 47 restricted government investment in key provinces, and a long - term mechanism for preventing local debt risks was gradually established [23][29]. - **Financing Platform Debts**: For financial debts, the policy strengthened both the support for resolving existing debts and the restriction on new debts, using new tools such as unified borrowing and repayment of urban investment bonds, syndicated loans to replace non - standard debts, and central emergency liquidity loans. For arrears, the policy's efforts to control growth and resolve stocks were relatively limited [33][42]. 3.2 Policy Effects: Slowed Debt Growth and Mitigated Debt Risks - **Urban Investment Debts**: The growth rate of urban investment interest - bearing debt decreased, especially in key provinces. The debt structure improved, the annual interest - payment rate decreased, and the credit spreads of urban investment bonds narrowed significantly. The number of debt - risk public opinions also decreased [46][56][58]. - **Local Debts**: The growth rate of local debts decreased, and the difference with the social financing growth rate narrowed. The proportion of urban investment interest - bearing debt in local debts decreased, indicating an improved debt structure. The growth rate of local government bonds declined, and the proportion of generalized replacement bonds increased [60][61][62]. 3.3 Policy Outlook: Ordered Withdrawal of Debt - Resolution and Promotion of Platform Transformation - **Most Debt - Resolution Policies Will Gradually Withdraw**: Fiscal and financial support for debt - resolution will decline. The scale of debt replacement may decrease significantly in the second half of 2026. The number of financing platforms has dropped by over 80%, and the policy may return to emphasizing local autonomous debt - resolution [65][66][67]. - **Accelerating the Clearance of Financing Platforms and Promoting Substantial Transformation**: In 2026, the central government will optimize debt - restructuring methods, including relaxing the pre - conditions for debt restructuring and promoting the trusteeship of implicit debts through "unified borrowing and repayment" to accelerate the platform - exit process. However, the substantial transformation of financing platforms remains a long - term task [74][75][77]. 3.4 Urban Investment Strategies: Spreads May Widen and Seek Safety Margins - **Low Default Risk but High Valuation Risk**: The default risk of urban investment bonds is expected to remain low, but there is a risk of valuation adjustment. From the perspectives of credit spreads, credit risks, and supply changes, the credit spreads of urban investment bonds are likely to widen [80][81]. - **Select Regions with Valuation Safety Margins and Entities with Clear Government Support**: In the short term, investors should be more vigilant about the regional differentiation risks caused by the withdrawal of central support. Regionally, focus on areas where bond yields are not overly compressed, such as Shanxi, Beijing, and Shanghai. At the entity level, pay attention to entities with clear government support, such as market - oriented declaration entities [84][85][86].

Investment Rating - The investment rating for the company is "Recommended" [1] Core Views - The company achieved a significant increase in revenue and net profit due to a vibrant market, with total revenue reaching 16.068 billion yuan (YOY +38.5%) and net profit at 12.085 billion yuan (YOY +25.75%) for the year 2025 [4][10] - The company's brokerage business revenue grew substantially, reaching 12.535 billion yuan (YOY +47.59%), driven by increased trading activity in the A-share market [10] - The company maintains a strong market presence with a well-established network and is leveraging AI capabilities to enhance its financial services [10] Summary by Relevant Sections Financial Performance - Total revenue for 2025 was 16.068 billion yuan, with a year-over-year growth of 38.5% [4] - Net profit for 2025 was 12.085 billion yuan, reflecting a year-over-year increase of 25.75% [4] - The company's total assets reached 392.934 billion yuan, up 28.25% year-over-year [4] Revenue Breakdown - Brokerage business net income was 8.662 billion yuan, growing by 44.1% year-over-year [10] - Fund distribution revenue was 3.182 billion yuan, with a year-over-year increase of 12.0% [10] - Financial data revenue reached 240 million yuan, up 25.18% year-over-year [10] Market Position - The average daily trading volume in the A-share market was 20.538 billion yuan, an increase of 69.71% year-over-year [10] - The company's market share in brokerage business was estimated at 3.85%, a slight decrease of 0.29 percentage points year-over-year [10] - The company's margin financing balance reached 78.894 billion yuan, with a year-over-year growth of 37.3% [10] Future Projections - Revenue projections for 2026 are estimated at 17.475 billion yuan, with a growth rate of 8.8% [6] - Net profit for 2026 is projected to be 13.840 billion yuan, reflecting a growth rate of 14.5% [6] - The company expects to maintain a high net profit margin, with projections of 79.2% for 2026 [11]

Investment Rating - Industry investment rating: Outperform the market (expected to outperform the market index by more than 5% in the next 6 months) [61] Core Viewpoints - Precious Metals - Gold: The escalation of the Middle East situation has led to a decrease in gold prices, with COMEX gold futures reaching $4,492 per ounce, down 10.57% month-on-month. SPDR Gold ETF holdings decreased by 1.4% to 1,057 tons. The geopolitical situation is expected to continue impacting liquidity and gold prices in the short term, while the long-term pricing framework for gold remains unchanged [5][8]. - Industrial Metals: Increased geopolitical disturbances have put downward pressure on industrial metals. Copper prices fell by 5.55% to 94,740 RMB/ton, with domestic copper social inventory at 523,100 tons. Aluminum prices decreased by 3.8% to 24,020 RMB/ton, with domestic aluminum social inventory at 1,339,000 tons. Tin prices dropped by 8.5% to 342,500 RMB/ton, with domestic tin social inventory at 10,977 tons. The geopolitical situation is expected to continue affecting market sentiment [6][7][8]. Summary by Sections 1. Nonferrous Metal Index Trends - As of March 22, 2026, the nonferrous metal index closed at 9,356.16 points, down 12.3% month-on-month. The precious metal index fell by 10.7% to 29,454.22 points, the industrial metal index decreased by 13.3% to 3,337.03 points, and the energy metal index dropped by 10.8% to 2,683.75 points [11]. 2. Precious Metals - Gold: The macroeconomic uncertainties continue to amplify gold's safe-haven attributes. The long-term trend indicates a weakening of the dollar's credit status, enhancing gold's monetary properties. The recommendation is to focus on Chifeng Gold [8][59]. 3. Industrial Metals - Copper: Domestic demand is gradually recovering, and the global demand for refined copper is expected to open up long-term space. The recommendation is to focus on Luoyang Molybdenum [8][59]. - Aluminum: The weak supply and strong demand dynamics are expected to accelerate, with aluminum prices likely to continue rising. The recommendation is to focus on Tianshan Aluminum [8][59]. - Tin: The development of AI technology is expected to increase demand for tin, but geopolitical factors remain a significant influence on market sentiment [7][8]. 4. Energy Metals - Lithium: The report includes insights on lithium prices and market dynamics, indicating ongoing trends in supply and demand [46]. 5. Investment Recommendations - The report suggests focusing on the gold, copper, and aluminum sectors due to their respective market dynamics and potential for growth [8][59].

Investment Rating - The report maintains a "Buy" recommendation for 康哲药业 (0867.HK) with a current stock price of 13.59 HKD [1][3]. Core Insights - 康哲药业's revenue for 2025 reached 82.12 billion CNY, representing a year-on-year growth of 9.9%. The normalized annual profit was 17.76 billion CNY, showing a growth of 3.6% after excluding a one-time tax payment of 2.79 billion CNY [4][7]. - The company is experiencing a harvest period for its innovative products, with sales from core innovative and exclusive drugs reaching 56.13 billion CNY, a growth of 23.3% [7][8]. - The company is accelerating its innovation and research, with two new drugs approved for market release in early 2026, contributing to its growth strategy [7][8]. Financial Summary - Revenue projections for 康哲药业 are as follows: 98.33 billion CNY in 2026, 116.45 billion CNY in 2027, and 139.43 billion CNY in 2028, with growth rates of 19.7%, 18.4%, and 19.7% respectively [6][8]. - Net profit estimates are projected at 19.79 billion CNY for 2026, 22.80 billion CNY for 2027, and 27.16 billion CNY for 2028, with growth rates of 32.9%, 15.2%, and 19.1% respectively [6][8]. - The gross margin is expected to stabilize around 72.5% in 2026, with a net margin of 19.8% [6][8].

1. Report Industry Investment Rating No information about the industry investment rating is provided in the content. 2. Core Viewpoints of the Report - The performance of ETF products in the past two weeks was poor. Among domestic major broad - based ETFs, CSI A50 had the smallest decline, and among industry and theme products, new energy theme ETFs had the largest increase [2][9]. - In the past two weeks, among domestic major broad - based ETFs, the net inflow of funds into Science and Technology Innovation 50, SSE 50, CSI 500, and SSE - SZSE 300 ETFs ranked among the top [2][9]. - The net outflow of funds from major broad - based ETFs in the past two weeks slowed down. The funds of SSE - SZSE 300, SSE 50, and CSI 500 ETFs turned into net inflow, the net outflow of funds from CSI 1000/CSI 2000 and Science and Technology Innovation/ChiNext ETFs slowed down, and the net outflow of funds from A - series ETFs accelerated [10]. - In 2025, the technology theme ETF had a large cumulative net inflow of funds. Since this year, the technology and cyclical theme ETFs have had a large net inflow of funds. In the past two weeks, the inflow of funds into pharmaceutical, military, and new energy ETFs slowed down, the funds of dividend, consumption, and other large - manufacturing ETFs turned into net inflow, and the funds of cyclical, financial real - estate, and technology ETFs turned into net outflow [15]. - Since 2025, the credit bond ETF has had a large net inflow of funds, followed by the treasury bond ETF. In the past two weeks, the short - term financing ETF's funds turned into net inflow, the local government bond ETF's funds accelerated net inflow, the convertible bond ETF's funds turned into net outflow, the credit bond and treasury bond ETF's funds accelerated outflow, and the net outflow of funds from the policy - financial bond ETF slowed down [15]. - The daily average trading volume of pharmaceutical and new energy ETFs increased significantly in the past two weeks, the daily average trading volume of consumption and financial real - estate ETFs increased, and the daily average trading volume of other large - manufacturing, military, technology, and cyclical ETFs decreased [18]. - As of March 20, 20 new ETFs were newly established in the market in the past two weeks, with a total issuance share of 6715 million, all of which were stock ETFs. Compared with the end of 2025, the scale of commodity ETFs, industry + dividend ETFs, and QDII - ETFs increased by 32.78%, 13.10%, and 2.11% respectively, while the scale of bond ETFs and broad - based ETFs decreased by 12.51% and 43.21% respectively [22]. - As of March 20, Huaxia Fund had the largest on - exchange ETF scale, reaching 70.3557 billion yuan; the ETF management scale of Guotai Fund has expanded by more than 2.7 billion yuan since the beginning of this year [23]. 3. Summary According to the Directory 3.1 ETF Market Review - **Performance and Fund Flow**: As of March 20, the performance of ETF products in the past two weeks was poor. Among domestic major broad - based ETFs, CSI A50 had the smallest decline, and among industry and theme products, new energy theme ETFs had the largest increase. In the past two weeks, among domestic major broad - based ETFs, the net inflow of funds into Science and Technology Innovation 50, SSE 50, CSI 500, and SSE - SZSE 300 ETFs ranked among the top. The inflow of funds into pharmaceutical, military, and new energy ETFs slowed down, the funds of dividend, consumption, and other large - manufacturing ETFs turned into net inflow, the funds of cyclical, financial real - estate, and technology ETFs turned into net outflow. For bond ETFs, the short - term financing ETF's funds turned into net inflow, the local government bond ETF's funds accelerated net inflow, the convertible bond ETF's funds turned into net outflow, the credit bond and treasury bond ETF's funds accelerated outflow, and the net outflow of funds from the policy - financial bond ETF slowed down [2][9][15]. - **Product Structure Distribution**: As of March 20, 20 new ETFs were newly established in the market in the past two weeks, with a total issuance share of 6715 million, all of which were stock ETFs. Compared with the end of 2025, the scale of commodity ETFs, industry + dividend ETFs, and QDII - ETFs increased by 32.78%, 13.10%, and 2.11% respectively, while the scale of bond ETFs and broad - based ETFs decreased by 12.51% and 43.21% respectively [22]. - **Fund Manager Scale Distribution**: As of March 20, Huaxia Fund had the largest on - exchange ETF scale, reaching 70.3557 billion yuan; the ETF management scale of Guotai Fund has expanded by more than 2.7 billion yuan since the beginning of this year [23]. 3.2 Classification - based ETF Tracking - **Technology Theme ETF**: Products tracking the Hang Seng Technology Index had the highest net inflow of funds in the past two weeks, while products tracking the Hong Kong Stock Connect Internet Index had a net outflow of funds [29]. - **Dividend Theme ETF**: Products tracking the Dividend Low - Volatility Index had the highest net inflow of funds in the past two weeks, while products tracking the Guoxin Hong Kong Stock Connect Central Enterprise Dividend Index had a net outflow of funds [31]. - **Consumption Theme ETF**: Products tracking the S&P 500 Consumer Select Index had a relatively high premium rate; ETFs tracking the CSI Agriculture Index had the highest net inflow of funds in the past two weeks, while products tracking the CSI 800 Consumption Index had a net outflow of funds [34]. - **Pharmaceutical Theme ETF**: ETFs tracking the CSI Medical Index had the highest net inflow of funds in the past two weeks, while products tracking the medical device index had a net outflow of funds [36]. - **Large - Manufacturing Theme ETF**: Products tracking the power index had the highest net inflow of funds in the past two weeks, while products tracking the CS Battery Index had a net outflow of funds [39]. - **QDII ETF**: Products tracking the Hang Seng Technology Index had the highest net inflow of funds in the past two weeks, while ETF products tracking the Hang Seng China Enterprises Index had a net outflow of funds [42]. 3.3 Popular Theme ETF Tracking - **AI Theme ETF**: The average return of AI theme products in the past two weeks was - 2.89%, and the funds had a net outflow of 4.218 billion yuan. The products with a relatively high proportion of AI - themed stocks were those tracking the Hong Kong Stock Connect Internet, Hang Seng Internet Technology, CS Artificial Intelligence, etc. [48][53]. - **Robot Theme ETF**: The average return of robot theme products in the past two weeks was - 6.81%, and the funds had a net outflow of 488 million yuan. The products with a relatively high proportion of robot - themed stocks were those tracking the robot and robot industry [55][56]. - **New Energy Theme ETF**: The average return of new energy theme products in the past two weeks was 3.27%, and the funds had a net inflow of 1.126 billion yuan. The products with a relatively high proportion of new - energy - themed stocks were those tracking new energy batteries, CS batteries, etc. [58][59]. - **Satellite and Commercial Space Theme ETF**: The average return of satellite and commercial space theme products in the past two weeks was - 9.35%, and the funds had a net outflow of 661 million yuan. The products tracking satellite communication, satellite industry, and Guozheng Aerospace had such characteristics [60][64]. - **Commodity ETF**: The average return of commodity ETFs in the past two weeks was - 0.89%, and the funds had a net inflow of 6.011 billion yuan. Products tracking gold, non - ferrous metal futures, etc. were included. Since the beginning of this year, gold ETFs have had a large net inflow of funds, with a large net outflow on February 3 [65][70]. - **Central Huijin, Guoxin, and Chengtong Holdings ETF**: As of the middle of 2025, the scale of ETFs held by Central Huijin, Guoxin, and Chengtong was 39.1336 billion shares in total; in the past two weeks, the funds had a net outflow of 2.3474 billion yuan [73].

Group 1: Geopolitical and Economic Context - The ongoing US-Iran conflict has escalated, impacting energy facilities in Gulf countries, with significant disruptions in shipping through the Strait of Hormuz, averaging only about 2 cargo ships and less than 0.5 oil tankers per day[2][6] - Global central banks have collectively adopted a hawkish stance, with the US Federal Reserve maintaining its target federal funds rate at 3.5-3.75% and delaying the next rate cut expectation to September 2027[5][9] - The market anticipates that if oil prices remain above $100 per barrel, US CPI could rise to between 3.46% and 3.92%[9][19] Group 2: Market Performance - Asian markets showed some recovery, with South Korea up 5.4%, Singapore up 2.2%, and Malaysia up 1.3%, driven by AI sector growth and lower exposure to Middle Eastern energy shocks[11][13] - Major global stock indices, including the S&P 500 and European STOXX600, experienced declines of 1.90% and 3.79% respectively, reflecting the broader market's reaction to geopolitical tensions[16][12] - Brent crude oil prices rose by 8.8% to $112.19 per barrel, while WTI prices saw a slight decrease of 0.5% to $98.2 per barrel, indicating a widening price gap due to geopolitical risks[19] Group 3: Inflation and Economic Indicators - The US Producer Price Index (PPI) for February increased by 0.7% month-on-month and 3.4% year-on-year, exceeding expectations and indicating rising inflation pressures[9][10] - Industrial production in the US showed a month-on-month decline of 0.15%, while initial jobless claims remained stable at 205,000, suggesting a mixed economic outlook[9][10] - The Australian central bank raised its interest rate to 4.1%, with expectations for 2-3 more hikes this year, reflecting concerns over inflation driven by the conflict[9][19]

Investment Rating - The industry investment rating is "Outperform the Market," indicating an expected performance exceeding the market by more than 5% within the next six months [54]. Core Insights - The global population affected by multiple sclerosis (MS) is substantial, with over 2 million patients worldwide, particularly prevalent in Europe and the United States. The disease primarily affects individuals aged 20-40, with a significant economic burden, as the costs in the U.S. alone exceed $24 billion [3][6]. - Current therapies for MS include CD20 monoclonal antibodies, which dominate the market. Notably, Roche's Ocrelizumab is projected to generate approximately $9 billion in sales by 2025, while Novartis's Ofatumumab is expected to reach $4.426 billion [3][17]. - BTK inhibitors are emerging as a promising new treatment option for MS, targeting both adaptive and innate immune mechanisms. Several companies, including Sanofi, Roche, and Novartis, are advancing their BTK inhibitors through clinical trials, with significant results expected in the near future [3][24][30][34]. Summary by Sections 1. Global Patient Population of Multiple Sclerosis - MS is characterized by inflammatory demyelination in the central nervous system, with symptoms including vision loss and motor impairment. The disease typically begins between the ages of 20 and 40, with a global prevalence of approximately 2.99 million patients as of 2022 [6][10]. 2. BTK Inhibitors as a New Treatment Option - BTK inhibitors are significant due to their ability to modulate B cell and myeloid cell activity, making them potential treatments for MS. Several BTK inhibitors are in clinical development, with promising results from trials conducted by companies like Sanofi and Roche [24][30][34]. 3. Investment Recommendations - The report recommends focusing on companies with advanced pipelines in the MS treatment space, particularly those with BTK inhibitors in late-stage clinical trials, such as Novartis's Remibrutinib and Innovent Biologics's Orelabrutinib [50].

Investment Rating - The industry investment rating is "stronger than the market" (预计6个月内，行业指数表现强于市场表现5%以上) [34] Core Insights - The domestic pharmaceutical industry is showcasing innovative pipelines at the 2026 AACR conference, indicating a strong competitive edge globally [5] - Investment strategies suggest focusing on innovative treatment areas such as metabolic diseases, chronic diseases, and central nervous system disorders, as well as potential technology platforms like small nucleic acid drugs and CAR-T therapies [6] - The report highlights a slight increase in pharmaceutical financing and a recovery in BD transactions and H-share IPOs, which are revitalizing innovation enthusiasm [6] Summary by Sections Industry Overview - The 2026 AACR conference will take place in San Diego, featuring numerous innovative pharmaceutical companies discussing breakthroughs from basic research to clinical translation [5] - Key presentations include Merck's disclosure of clinical data for MK-2010, Revolution's updates on Pan-Ras assets, and various other companies showcasing their clinical and preclinical data [5] Investment Strategy - The report recommends focusing on companies with strong potential in innovative drug development, including Baiyi Shenzhou, He Yu-B, and others [6] - It emphasizes the growth of external CXO demand and suggests monitoring companies involved in emerging fields like peptides and small nucleic acids [6] Market Performance - The pharmaceutical sector experienced a decline of 2.77% last week, while the Shanghai and Shenzhen 300 index fell by 2.19%, ranking the pharmaceutical industry 8th among 28 sectors [10][19] - The valuation of the pharmaceutical sector is reported at 28.87 times (TTM), with a premium of 6.85% over the overall A-shares [25]